While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Intensive chemotherapy combined with second- or third-generation tyrosine kinase inhibitors improves survival in patients ...

A group of researchers at VCU Massey Comprehensive Cancer Center was awarded $13 million by the National Cancer Institute.

Pre-eclampsia dey lead to 70,000 maternal deaths annually, but how e take start still be mystery. Dis article torchlight ...

The cost of SARMs can vary depending on the supplier, dosage, and cycle length. Typically, SARMs range from $80 to $200 per ...

Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral ...

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.

The ASC4FIRST trial explores asciminib for chronic myeloid leukaemia, but experts question its design and outcomes, ...